Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 3Phase NA 1Phase 2/3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Rectal Neoplasms 3Breast Neoplasms 3Esophageal Squamous Cell Carcinoma 2Colonic Neoplasms 2Carcinoma, Hepatocellular 2Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oesophagogastric Cancer 1Neoplasms 1Inflammatory Breast Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 2Taxes 1Neoadjuvant Therapy 1Letrozole 1Lapatinib 1Gonadotropin-Releasing Hormone 1Doxorubicin 1Cisplatin 1Carboplatin 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Inflammatory Breast Neoplasms × Neoadjuvant Therapy × Clear all
NCT00397761 2021-02-17

Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer

Medstar Health Research Institute

Phase 2/3 Withdrawn
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡